Updated information for patients and healthcare professionals using valproate (Epilim) and topiramate (Topamax)

News Category: Regulatory news

Date: 11/06/2024

The HPRA has updated its website to include new and updated information for topiramate and valproate medicines.

The educational materials provide information for patients and healthcare professionals and were developed to support these medicines' safe and appropriate use.

Valproate (Epilim)

Female patients

While the conditions of valproate's pregnancy prevention program (‘prevent’) remain unchanged, the supporting educational materials have been updated to enhance their clarity and usability.

Visit use of valproate in women of childbearing potential and during pregnancy. Where updated materials are available, they are marked on the webpage as ‘new version’.

Male patients

Following the introduction of precautionary measures for male patients prescribed valproate, new educational materials are available to support the implementation of these measures in clinical practice.

Visit use of valproate in male patients.


With the introduction of measures to avoid topiramate exposure during pregnancy, including a pregnancy prevention program, new educational materials are now available to support these efforts in clinical practice.

Visit topiramate (Topamax ▼) pregnancy prevention programme and restrictions on use.

« Back